Novartis to cut 2,200 jobs in Switzerland to boost profitsNovartis has announced that it will cut 2,200 jobs in Switzerland to boost its profitability. The company told Share XNovartis to cut 2,200 jobs in Switzerland to boost profitshttps://pharmaphorum.com/news/novartis-to-cut-2200-jobs-in-switzerland-to-boost-profits/
Gilead launches generics of own hepatitis C drugs in US to cut health costsGilead is to launch cheaper generic versions of its hepatitis C drugs in the US, responding to calls Share XGilead launches generics of own hepatitis C drugs in US to cut health costshttps://pharmaphorum.com/news/gilead-launches-generics-of-own-hepatitis-c-drugs-in-us-to-cut-health-costs/
Merck and Pfizer trial cancer combination with Australia’s ImmutepAustralian biotech Immutep has begun a clinical trial partnership with Germany’s Merck KGaA and Pfizer to develop a Share XMerck and Pfizer trial cancer combination with Australia’s Immutephttps://pharmaphorum.com/news/merck-and-pfizer-trial-cancer-combination-with-australias-immutep/
Roche aims to improve cancer treatments with DNA blood testRoche has launched a blood test that can identify 70 of the most commonly mutated genes in solid Share XRoche aims to improve cancer treatments with DNA blood testhttps://pharmaphorum.com/news/roche-aims-to-improve-cancer-treatments-with-dna-blood-test/
Public inquiry investigates thousands of deaths from infected NHS bloodA public inquiry has opened to look into how infected NHS blood killed more than 2,900 people since Share XPublic inquiry investigates thousands of deaths from infected NHS bloodhttps://pharmaphorum.com/news/public-inquiry-investigates-thousands-of-deaths-from-infected-blood-on-nhs/
Underinvestment in medtech threatens sector growth – EYUnderinvestment in medical technology could threaten growth in the sector, according to a report by Ernst & Young Share XUnderinvestment in medtech threatens sector growth – EYhttps://pharmaphorum.com/digital/underinvestment-in-medtech-threatens-sector-growth-ey/
Study shows AZ’s Farxiga diabetes drug cuts heart risksAstraZeneca’s Farxiga has become the latest type 2 diabetes drug to show it can reduce cardiovascular risk in Share XStudy shows AZ’s Farxiga diabetes drug cuts heart riskshttps://pharmaphorum.com/news/study-shows-azs-farxiga-diabetes-drug-cuts-heart-risks/
Novartis, Bayer consider appeal as court says Avastin can be used in AMDEngland’s High Court has ruled it is lawful to use Roche’s Avastin (bevacizumab) in an unlicensed use in Share XNovartis, Bayer consider appeal as court says Avastin can be used in AMDhttps://pharmaphorum.com/news/novartis-bayer-consider-appeal-as-court-says-avastin-can-be-used-in-amd/
Bedrock, DDB and Insypher lead at PM Society Digital Awards 2018Bedrock, DDB Remedy and Insypher each scored two Golds at last night’s PM Society Digital Awards 2018 in Share XBedrock, DDB and Insypher lead at PM Society Digital Awards 2018https://pharmaphorum.com/news/pm-society-digital-awards-2018/
Spark/Novartis eye gene therapy nears EU market – but at what price?Spark Therapeutics’ and Novartis Luxturna gene therapy for a rare inherited eye disease has been okayed by European Share XSpark/Novartis eye gene therapy nears EU market – but at what price?https://pharmaphorum.com/news/spark-novartis-eye-gene-therapy-luxturna/
EU regulators back Ipsen cancer drug in new liver cancer useIpsen’s bid to build a cancer franchise around its Cabometyx (cabozantinib) is gathering pace after European regulators backed Share XEU regulators back Ipsen cancer drug in new liver cancer usehttps://pharmaphorum.com/news/eu-regulators-cabometyx-liver/
MPs call for NHS funding for HIV prevention drugLeading UK politicians have called for an HIV prevention drug to be made available across the NHS, after Share XMPs call for NHS funding for HIV prevention drughttps://pharmaphorum.com/news/mps-call-for-nhs-funding-for-hiv-truvada/
Pharma body agrees five-year deal to boost NHS innovationThe UK’s pharma trade body, the Association of the British Pharmaceutical Industry (ABPI), has signed a five-year partnership Share XPharma body agrees five-year deal to boost NHS innovationhttps://pharmaphorum.com/news/abpi-agrees-five-year-deal-to-boost-nhs-innovation/
Celgene passes on OncoMed cancer drug, biotech’s shares tankCelgene has decided against taking an option on Oncomed’s cancer drug navicixizumab, sending the California biotech’s shares into Share XCelgene passes on OncoMed cancer drug, biotech’s shares tankhttps://pharmaphorum.com/news/celgene-passes-on-oncomed-cancer-drug-biotechs-shares-tank/
UK public-private partnership to use AI to cut drug failure rateA UK R&D project has secured a government grant to help its artificial intelligence (AI)-based drug discovery project. Share XUK public-private partnership to use AI to cut drug failure ratehttps://pharmaphorum.com/news/uk-public-private-partnership-to-use-ai-to-cut-drug-failure-rate/
AZ expands role in China, to include robots and health techAstraZeneca is planning to expand its role as a drug supplier in China to becoming a wider provider Share XAZ expands role in China, to include robots and health techhttps://pharmaphorum.com/news/az-expands-role-in-china-to-include-robots-and-health-tech/
Mylan and Fujifilm join Humira bunfight as fifth EU biosimilar approvedMylan and Fujifilm Kyowa Kirin Biologics have got their Humira biosimilar approved in Europe – the fifth cut-price Share XMylan and Fujifilm join Humira bunfight as fifth EU biosimilar approvedhttps://pharmaphorum.com/news/mylan-and-fujifilm-biosimilar-approved/
Pharma depriving developing countries of taxes – reportA damning report by Oxfam claims that pharma giants are ‘depriving’ developing countries of millions of dollars’ worth Share XPharma depriving developing countries of taxes – reporthttps://pharmaphorum.com/news/pharma-depriving-developing-countries-of-taxes-report/
Immuno-Oncology 2018 News: MHRA Interview and New Speaker ImmuneBiotech AB Announced Share XImmuno-Oncology 2018 News: MHRA Interview and New Speaker ImmuneBiotech AB Announcedhttps://pharmaphorum.com/partner-content/immuno-oncology-2018-news-mhra-interview-and-new-speaker-immunebiotech-ab-announced/
Only 4 Weeks Until Orphan Drugs & Rare Diseases 2018 Share XOnly 4 Weeks Until Orphan Drugs & Rare Diseases 2018https://pharmaphorum.com/partner-content/only-4-weeks-until-orphan-drugs-rare-diseases-2018/
Antibiotic Class Emerges through Digestive Enzyme Share XAntibiotic Class Emerges through Digestive Enzymehttps://pharmaphorum.com/partner-content/antibiotic-class-emerges-through-digestive-enzyme-2/
Achieving Controlled Nucleation During Aseptic Lyophilization Share XAchieving Controlled Nucleation During Aseptic Lyophilizationhttps://pharmaphorum.com/partner-content/achieving-controlled-nucleation-during-aseptic-lyophilization/
Carina Schey, University of Groningen, Orphan Drugs & Rare Diseases Chair Invitation Share XCarina Schey, University of Groningen, Orphan Drugs & Rare Diseases Chair Invitationhttps://pharmaphorum.com/partner-content/carina-schey-university-of-groningen-orphan-drugs-rare-diseases-chair-invitation/
Corporate Communications chief of Astellas, Jo Taylor moves to Cello Health Communications Share XCorporate Communications chief of Astellas, Jo Taylor moves to Cello Health Communicationshttps://pharmaphorum.com/partner-content/corporate-communications-chief-of-astellas-jo-taylor-moves-to-cello-health-communications/
